About this Research Topic
Hepatocellular Carcinoma (HCC) does not only seriously endanger the physical and mental health of patients, but also poses a significant challenge to public health. The majority of patients diagnosed with advanced HCC are not able to receive radical treatment, such as surgery, therefore targeted molecular therapy (i.e. oral protein kinase inhibitors) is the main therapeutic strategy effective for advanced HCC.
Although molecularly targeted drugs, such as Sorafenib, can delay the progression of HCC disease and prolong patient survival, they still present a number of challenges: (1) Sorafenib treatment in advanced HCC patients- there are individual differences in the initial sensitivity of patients to Sorafenib, and most patients who initially respond well to Sorafenib will eventually develop drug tolerance as the treatment progresses; (2) Existing treatment strategies (e.g. Sorafenib treatment requires oral high-dose of [800mg per day]) can cause serious side effects while treating cancer; (3) Recently, Lenvatinib has been approved as a first-line therapy, and Regorafenib as a second-line therapy, with hope that there may be further reports reviewing their tolerance in the future. Finally, the cost of HCC targeted drug therapy is remains highly expensive. Considering these challenges, it is necessary to seek novel therapeutic strategies for HCC treatment.
In this Research Topic, we aim to provide an overview of the recent progress around HCC treatment, encompassing relevant basic and translational studies.
We welcome submission of Original Research, Mini Review and Review articles focusing on the sub-topics below:
• Molecular mechanisms related to HCC
• Small molecule inhibitors with new structures for HCC
• Clinical application of surgical robots
• New long-acting and sustained-release anti-tumor drugs
• Nanomedicine and materials for HCC treatment
• Molecular markers based on novel clinical laboratory technology
Please note: for manuscripts submitted in consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for Frontiers in Oncology, Molecular and Cellular Oncology section and will not be accepted as part of this Research Topic in the said section.
Although molecularly targeted drugs, such as Sorafenib, can delay the progression of HCC disease and prolong patient survival, they still present a number of challenges: (1) Sorafenib treatment in advanced HCC patients- there are individual differences in the initial sensitivity of patients to Sorafenib, and most patients who initially respond well to Sorafenib will eventually develop drug tolerance as the treatment progresses; (2) Existing treatment strategies (e.g. Sorafenib treatment requires oral high-dose of [800mg per day]) can cause serious side effects while treating cancer; (3) Recently, Lenvatinib has been approved as a first-line therapy, and Regorafenib as a second-line therapy, with hope that there may be further reports reviewing their tolerance in the future. Finally, the cost of HCC targeted drug therapy is remains highly expensive. Considering these challenges, it is necessary to seek novel therapeutic strategies for HCC treatment.
In this Research Topic, we aim to provide an overview of the recent progress around HCC treatment, encompassing relevant basic and translational studies.
We welcome submission of Original Research, Mini Review and Review articles focusing on the sub-topics below:
• Molecular mechanisms related to HCC
• Small molecule inhibitors with new structures for HCC
• Clinical application of surgical robots
• New long-acting and sustained-release anti-tumor drugs
• Nanomedicine and materials for HCC treatment
• Molecular markers based on novel clinical laboratory technology
Please note: for manuscripts submitted in consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for Frontiers in Oncology, Molecular and Cellular Oncology section and will not be accepted as part of this Research Topic in the said section.
Keywords: Molecular targeted agents, Nano-medicine, Novel medical materials, Long-acting sustained-releasing agents, New molecular markers
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
